Abstract
The perioperative combination of 5‐fluorouracil, oxaliplatin, and docetaxel is a new standard treatment in patients with esophageal carcinoma. However, chemoradiation results in higher R0 surgical resection rates, pathologic complete response, and negative lymph node status. The identification of molecular subsets may influence the design of future studies and guide drug development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
